Wegovy pen doses: how the titration schedule works in practice

You've just been handed your first pen, here's what those four doses are actually doing

Picture the scenario most people arrive at: the pen is in the fridge, the instructions feel dense, and the question nobody quite answers is whether one pen equals one step on the schedule or something more complicated.

The simple answer is yes, one pen equals one step. If you want to understand exactly how a Wegovy one pen four doses arrangement maps onto the weekly schedule, that page explains the structure in full. You inject once a week, four times, then move to the next pen at the next strength, assuming your prescriber confirms you're ready. The NHS medicines page for semaglutide sets out this escalation clearly, and it is the same for private patients.

The first pen delivers 0.25 mg per week. That dose is a settling-in dose. Its job is to acclimatise your gut to semaglutide, not to produce significant appetite suppression yet. Most people notice mild nausea in the first week or two; for many it settles before the pen runs out. Knowing that in advance makes the early weeks considerably less alarming.

At week five, you move to the 0.5 mg pen. By week nine, 1.0 mg. Week thirteen brings 1.7 mg, and the standard maintenance dose of 2.4 mg begins around week seventeen. The full Wegovy dose schedule covers what happens at each stage in more detail, including the circumstances in which a prescriber might extend a lower dose rather than escalate.

A practical note on timing: if your first delivery arrives on a Monday (or just after payday, when many people start) week five falls on the same weekday, which makes it easy to track without a spreadsheet. Consistency of timing helps, though the SmPC on the eMC confirms you have flexibility of a day or two if needed.

How many doses are in a Wegovy pen, and does the 7.2 mg pen work differently?

For the standard titration pens (0.25 mg through 2.4 mg), the Wegovy 4 dose pen design means one pen covers four weeks at one strength. You do not dial a dose; the pen is pre-set. Press the button, hold for the count, done.

The 7.2 mg pen is different. The MHRA approved a dedicated single-dose 7.2 mg pen on 14 April 2026, one pre-set injection per week, auto-dosing mechanism, built-in covered needle that locks after use, and no multi-dose reservoir. This pen is licensed only for adults with a BMI of 30 or above, and only for weight management; it is not interchangeable with the 2.4 mg pen for the cardiovascular indication. The government's announcement of the single-dose 7.2 mg semaglutide pen approval confirms the design and the licensed population.

Reaching 7.2 mg still requires completing the standard titration first. A prescriber will not move someone directly from 1.0 mg to 7.2 mg. The 2.4 mg maintenance phase comes first, and 7.2 mg is an extension for those who tolerate and have completed the standard schedule. To understand more about how a single Wegovy pen delivers its four doses, that page walks through the mechanics.

If you're considering what the higher dose might mean for results, the STEP trials reported an average weight reduction of around 15% at 2.4 mg over 68 weeks in the STEP 1 study, published in the New England Journal of Medicine. Trial data at 7.2 mg showed results approaching around 20.7% on average over 72 weeks, closing the gap with tirzepatide. Those are population averages from controlled conditions; individual results vary.

What disrupts the schedule, and what to do about it

Real life interrupts tidy four-week plans. A hospital stay, a holiday, a pen that arrives later than expected, or a run of side effects that makes escalating feel unwise, all of these happen, and all of them are worth raising with your prescriber rather than guessing.

The general principle from clinical guidance is that if you miss a single dose and your next scheduled dose is more than five days away, you take the missed dose. If it's closer than five days, skip it and resume the usual day. But that principle has nuances depending on where you are in the titration, and the specific wording in the patient information leaflet always takes precedence over general guidance read online.

Pausing treatment for more than a few weeks (planned surgery, pregnancy, or other reasons) may mean restarting at a lower strength rather than picking up where you left off. That's a clinical decision, not something to navigate alone. Our prescribers are available seven days a week for aftercare questions, and a quick message through our support team is the right starting point if something changes mid-schedule.

One thing that often surprises people: dose increases are not automatic at every review. If nausea or other side effects remain significant at the current level, a prescriber may recommend staying at that strength for another four weeks. That is not a setback, it reflects how the titration is supposed to work. The mechanics of a single pen dose and what to expect injection by injection are covered separately if the technique itself feels uncertain.

Wegovy is licensed for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. Whether the schedule suits your specific situation is always a clinical judgement. If you'd like a broader overview of the treatment itself, our Wegovy information page sets out how the medication works and who it is suitable for, before you explore cost and access through our weight-loss treatment overview.

Semaglutide is a prescription-only medicine. None of the above replaces a consultation with a qualified prescriber who can review your full health picture before any treatment begins. When you're ready to take that step, you can start your free consultation with nume, the same day, reviewed by a GPhC-registered Independent Prescriber.